Name: Responsive Respiratory Camera Style M4, M6, M9 Cylinder Carry Case,16 x 5.5 x 5.5,Each,150-1130
Brand: RESPONSIVE RESPIRATORY INC
SKU: 1187866399
Price: 57.09 USD
Availability: InStock

Responsive Respiratory Camera Style M4, M6, M9 Cylinder Carry Case,16 x 5.5 x 5.5,Each,150-1130 - 1187866399

By RESPONSIVE RESPIRATORY INC

$57.09

(149 Reviews)

Model

1187866399

Store

Health Products For You
Premium Online Retailer Of Health Products, Medical Supplies & HomeCare Medical Equipments. Healthcare & Healthy Living Store. Affordable Healthcare Essentials.

Manufacturer

RESPONSIVE RESPIRATORY INC

Detail

Responsive Respiratory Camera Style M4, M6, M9 Cylinder Carry Case has clear window for easy status checks. It comes with adjustable, detachable straps for comfort and has a quick carry handle at top of bag. Vented for conserver use. This carry case has interior Velcro cylinder stabilizer strap and roomy interior. It also includes grommeted cannula/tubing guides.

Category

Respiratory

Extract The airway epithelium plays a central role in the initiation and development of chronic airway diseases [1]. It is the first line of defence against the external environment; therefore, numerous inflammatory and tissue remodelling pathways exist to protect against damage caused by constant exposure to inhaled stimuli ( e.g. allergens, cigarette smoke or pathogens) [1, 2]. Dysregulation of these pathways alters the structure of the airway epithelium, making it an inadequate defence against further insult from inhaled stimuli. This results in a cycle of abnormal epithelial responses and further damage, which may contribute to irreversible airway changes and severe chronic airway disease, such as chronic obstructive pulmonary disease (COPD) [1, 2]. ...

>Read More

Background There is limited evidence on the pathways leading to severe asthma and we are presently unable to effectively predict the progression of the disease. We aimed to describe the longitudinal trajectories leading to severe asthma and to describe clinical events preceding disease progression in a nationwide population of patients with severe asthma. Methods We conducted an observational study based on Swedish data from the NORdic Dataset for aSThmA Research (NORDSTAR) research collaboration platform. We identified adult patients with severe asthma in 2018 according to the European Respiratory Society/American Thoracic Society definition and used latent class analysis to identify trajectories of asthma severity over a 10-year retrospective period from 2018. Results Among 169 128 asthma patients, we identified 4543 severe asthma patients. We identified four trajectories of...

>Read More

Background Current guidelines recommend 20–40 mg·day –1 of oral prednisolone for treating pulmonary sarcoidosis. Whether the higher dose (40 mg·day –1 ) can improve outcomes remains unknown. Methods We conducted an investigator-initiated, single-centre, open-label, parallel-group, randomised controlled trial ( ClinicalTrials.gov identifier NCT03265405). Consecutive subjects with pulmonary sarcoidosis were randomised (1:1) to receive either high-dose (40 mg·day –1 initial dose) or low-dose (20 mg·day –1 initial dose) oral prednisolone, tapered over 6 months. The primary outcome was the frequency of relapse or treatment failure at 18 months from randomisation. Key secondary outcomes included the time to relapse or treatment failure, overall response, change in forced vital capacity (FVC, in l...

>Read More

Background Cystic fibrosis (CF) is commonly characterised by thick respiratory mucus. From diagnosis, people with CF are prescribed daily physiotherapy, including airway clearance techniques (ACTs). ACTs consume a large proportion of treatment time, yet the efficacy and effectiveness of ACTs are poorly understood. This study aimed to evaluate associations between the quality and quantity of ACTs and lung function in children and young people with CF. Methods Project Fizzyo, a longitudinal observational cohort study in the UK, used remote monitoring with electronic pressure sensors attached to four different commercial ACT devices to record real-time, breath-by-breath pressure data during usual ACTs undertaken at home over 16 months in 145 children. ACTs were categorised either as conformant or not with current ACT recommendations based on breath pressure and length measuremen...

>Read More

Extract Interstitial lung disease (ILD) is a heterogeneous group of pulmonary disorders, characterised by diffuse parenchymal lung infiltration. Some ILD patients can develop a progressive fibrosing phenotype characterised by worsening fibrotic changes, decline in lung function over time, worsening symptoms and quality of life, and early mortality. Patients with this inexorable progression of disease are referred to as having progressive pulmonary fibrosis (PPF) [1]. This disease behaviour is associated with an autonomous progressive fibrotic evolution due to repetitive epithelial microinjuries, over-expression of fibrogenic growth factors, fibroblast proliferation and active collagen accumulation leading to progressive lung dysfunction [2, 3]. Although antifibrotic therapy does not stop progression, it slows the forced vital capacity (FVC) decline, making prompt identification of pat...

>Read More

Product Details for 1187866399